Press Releases SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Market Closed - Nasdaq Other stock markets 16:30:01 2024-05-03 EDT			5-day change	1st Jan Change
1.33 ^USD	-1.48%		-8.90%	+25.47%

05-01	SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	CI
04-29	SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level	05-01	AQ
SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study	04-29	AQ
SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update	03-28	AQ
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study	03-26	AQ
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET	03-19	AQ
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules	03-15	AQ
SELLAS Life Sciences : Material Event - Form 8-K	03-11	PU
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships	03-08	AQ
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference	03-01	AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time	02-29	AQ
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget	02-06	AQ
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference	01-25	AQ
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia	01-12	AQ
SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients	01-09	AQ
SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering	01-04	AQ
SELLAS Life Sciences Announces Proposed Public Offering	01-03	AQ
SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones	01-03	AQ
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo in Advanced Malignant Pleural Mesothelioma	12-28	AQ
SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma	12-27	AQ
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas	12-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Press Releases

Filters